CD19 and neoplasm: CRS and neurotoxicity were more common and severe after the initial CD19 CAR-T cell infusion than those following the sequential CD22 CAR-T cell infusion, which could be correlated with a higher pretreatment tumor burden before the first infusion and lower peak levels of CD22 CAR-T cells during the second infusion.